“showed a trend”

The 16 children with tumor at optic nerve transection, showed a trend toward higher five-year CSS if they were treated with adjuvant chemoradiation versus no adjuvant treatment (80.0% vs. 45.0%; P = 0.192).

These data showed a trend toward fewer reports of depression in the teprenone-treated group (odds ratio 0.63; 95% confidence interval [CI] 0.30–1.18; p = 0.1920).

Patients with low TOLLIP serum concentrations (<0.1135 ng/μL) showed a trend towards shorter progression-free survival with a higher rate of disease progression compared with the TOLLIP-high group (36% vs 19%, p=0.192, respectively) ( online supplemental figure S1 ).

A prospective cohort study involving 113 patients revealed that short-duration IA-CSI combined with mechanical thrombectomy (MT) significantly reduced final infarct volume ( p = 0.038), though 90-day functional independence (modified Rankin Scale, mRS 0–2) only showed a trend toward improvement (51.1% vs. 41.2%, p = 0.192) [ 10 ].

The mean spleen size showed no significant difference among any of the categories, although PMF patients with JAK2V617F mutation showed a trend towards higher prevalence of massive splenomegaly at diagnosis compared to patients without mutation (p=0.193 and p=0.090, respectively).

Further subgroup analysis of patients who received postoperative radiotherapy showed a trend toward a higher incidence of severe capsular contracture in the mesh group compared with the non-mesh group (20% vs. 7.7%, p=0.193).

Log-rank test showed a trend of shorter median OS (35.0 months vs. 56.4 months, p = 0.193) in the low TMB group, although the p -value were not significant (Fig.

Antibiotic-related adverse events and overall mortality were similar in both groups in our study, but infection-related mortality showed a trend toward favorable outcome in the postintervention group compared to the baseline group (43.8% vs 61%; P = .193), suggesting that optimizing antibiotic therapy does not lead to poor outcomes.

Although the presence of adhesions showed a trend toward an increased risk of higher pain (OR = 1.38; 95% CI: 0.85–2.23), this association did not reach significance ( p = 0.193). 3.3.5.

Additionally, several SNPs showed a trend toward statistical significance, including rs2516839 ( p = 0.195), rs10757278 ( p = 0.158), and rs2713604 ( p = 0.054), warranting further investigation in larger cohorts.

However, the WERP group showed a trend of longer MACEE-free survival than CC group (P=0.195) ( Figure 5 ).

Regarding postoperative recovery, the M-TLIF group showed a trend towards earlier ambulation (2.53 ± 0.58 days vs. 2.67 ± 0.43 days, P = 0.195) and full weight-bearing (8.19 ± 0.60 days vs. 8.39 ± 0.66 days, P = 0.146), as well as a slightly shorter surgical incision (8.74 ± 3.01 cm vs. 8.89 ± 2.08 cm, P = 0.780), although these differences were not statistically significant.

Educational level demonstrated a trend towards positive association with adherence (OR = 1.196, 95% CI: 0.962–1.487, p = 0.108), while rural residence showed a trend towards lower adherence (OR = 0.698, 95% CI: 0.405–1.204, p = 0.196) and higher income towards better adherence (OR = 1.345, 95% CI: 0.987–1.834, p = 0.061), though none achieved statistical significance.

Men with the C allele of the m.1382A>C polymorphism showed a trend for higher risk for T2D regardless of physical activity status measured by accelerometer (C allele, 13.1%; A allele, 10.8%; p = 0.196, Supplementary Table 1 top), however, when assessing potential contributors to T2D risk, the degree of physical activity, measured by accelerometer, and expressed as moderate- to vigorous-intensity physical activity (MVPA), correlated with lower risk for T2D in men with the C allele (MVPA beta = 0.023; p = 0.035; Supplementary Tables 4 , 5 ).

Patients with <50% areas of CMVR showed a trend towards anatomical success (p = 0.197) and functional success (p = 0.245).

Whereas response rate only showed a trend to be higher in patients with Her-2/ neu -phosphorylated breast cancer (47 vs 34%, P =0.197), both uni- and multivariate analyses revealed that the median progression-free survival under trastuzumab-based treatment was significantly longer in patients with Her-2/ neu -phosphorylated breast cancer–11.7 (95% CI 5.2–18.3) months–when compared to the progression-free survival of 4.5 (95% CI 3.4–5.6) months observed in patients with tumours lacking phosphorylated Her-2/ neu ( P =0.001).

Examination in the subgroup of patients younger than 60 years at diagnosis showed a trend for a longer OS regarding all SOCS1 mutations and for major mutations compared to the corresponding subgroup of patients with SOCS1 wildtype ( P = 0·197 and P = 0·072).

Independent-samples t -test showed a trend toward increased positivity in the antibody-functionalized group ( t (4) = −1.548, p = 0.197), and the calculated effect size was large (Cohen’s d = 1.26), supporting the biological relevance of this difference despite the limited sample size. 3.9.

Results: Although not statistically significant, TTN infants showed a trend toward higher inflammatory indices with median NL-r (2.54 vs. 1.75, p = 0.197) and SII-i (729,307.83 vs. 373,593.50, p = 0.276).

For OS, although rMDS-predicted responders showed a trend toward improved outcomes (log-rank test, P = 0.197), this did not reach statistical significance.

For instance, Irritability rating showed a trend to decrease from 9.59 ± 7.65 to 8.17 ± 7.13, changing by −1.41±4.33, t (17) = 1.35, p = 0.198, n.s.

The passive control group showed a trend for improvements in visual span ( p = .198, d = .45) and matrix span ( p = .115, d = .49).

The expression level of MMP-9 showed a trend of increase in the MSC + MNC-QQ supernatant compared to the MSC supernatant (416,915 ± 292,771 vs 20,725 ± 14,349, p = 0.198) ( Fig. 2 C). 3.3.

Also, patients with stage IB, grade 2 showed a trend to have higher recurrence than those with lower stage or grade (9.4% vs. 4.3%, p=0.199).

Morning treatment ( n = 158) showed a trend toward improved overall survival vs. afternoon ( n = 79); the median survival was 158 vs. 79 days ( p = 0.20, HR = 0.84, CI 95% 0.84–0.91).